Merck posts higher third-quarter sales as Keytruda offsets drop in HPV vaccine
Update: 2025-10-30
Description
Merck's Q3 revenue surged due to Keytruda's growth, but shares fell as they lowered their full-year forecast. Investors are concerned about Keytruda's competition and industry pressures. Merck is focusing on new drugs like Winrevair and Ohtuvayre to prepare for life after Keytruda. Gardasil sales dropped in China and Japan, but overall, earnings per share are expected to stay in line with earlier outlook.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
